By Josh Beckerman

 

Moderna Inc. discussed plans to address the Omicron Covid-19 variant, including a new variant-specific vaccine candidate known as mRNA-1273.529.

The company said it is testing three vaccine booster candidates against the variant.

The Omicron variant "includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape," the company said. "The combination of mutations represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity," Moderna said.

 

Write to Josh Beckerman at josh.beckerman@wsj.com

 

(END) Dow Jones Newswires

November 26, 2021 15:55 ET (20:55 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Moderna Charts.